Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844.

Google Scholar 

DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.

Google Scholar 

Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014;311(10):1045.

CAS  Google Scholar 

Bhanushali MJ, Gustafson T, Powell S, Conwit RA, Wolinsky JS, Cutter GR, et al. Recruitment of participants to a multiple sclerosis trial: the CombiRx experience. Clin Trials. 2014;11(2):159–66.

Google Scholar 

Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer’s disease clinical trials. Alzheimers Res Ther. 2010;2(6):34.

CAS  Google Scholar 

Baldi I, Lanera C, Berchialla P, Gregori D. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006–2015. BMJ Open. 2017;7(6):e013482.

Google Scholar 

Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283(20):2701–11.

CAS  Google Scholar 

Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer’s disease clinic patients for clinical trials. J Am Geriatr Soc. 1997;45(8):923–8.

CAS  Google Scholar 

Anderson TS, Ayanian JZ, Souza J, Landon BE. Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with medicare beneficiaries with Alzheimer disease and mild cognitive impairment. JAMA. 2021;326(16):1627.

Google Scholar 

Cummings J. Lessons learned from Alzheimer disease: clinical trials with negative outcomes: lessons learned from Alzheimer disease. Clin Transl Sci. 2018;11(2):147–52.

Google Scholar 

Elkins JS, Khatabi T, Fung L, Rootenberg J, Johnston SC. Recruiting subjects for acute stroke trials: a meta-analysis. Stroke. 2006;37(1):123–8.

Google Scholar 

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379–88.

CAS  Google Scholar 

Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819.

CAS  Google Scholar 

Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556–63.

CAS  Google Scholar 

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High dose B vitamin supplementation and cognitive decline in Alzheimer’s disease: a randomized controlled trial. JAMA J Am Med Assoc. 2008;300(15):1774–83.

CAS  Google Scholar 

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853–61.

CAS  Google Scholar 

Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–94.

CAS  Google Scholar 

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903.

CAS  Google Scholar 

Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017;88(18):1768–75.

CAS  Google Scholar 

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–91.

CAS  Google Scholar 

Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial. JAMA Neurol. 2020;77(9):1099.

Google Scholar 

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, et al. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2019;76(10):1219.

Google Scholar 

Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141(11):1356–64.

CAS  Google Scholar 

Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.

CAS  Google Scholar 

Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33–9.

CAS  Google Scholar 

Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65–70.

Google Scholar 

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251–83.

CAS  Google Scholar 

Fargo KN, Carrillo MC, Weiner MW, Potter WZ, Khachaturian Z. The crisis in recruitment for clinical trials in Alzheimer’s and dementia: an action plan for solutions. Alzheimers Dement. 2016;12(11):1113–5.

Google Scholar 

Lamberti MJ, Mathias A, Myles JE, Howe D, Getz K. Evaluating the impact of patient recruitment and retention practices. Drug Inf J. 2012;46(5):573–80.

Google Scholar 

Schneider LS. Recruitment methods for united states Alzheimer disease prevention trials. J Nutr Health Aging. 2012;16(4):331–5.

CAS  Google Scholar 

Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting low accrual in the National Cancer Institute’s Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016;108(2):djv324.

Google Scholar 

Saver JL. Coping with an embarrassment of riches. Stroke. 1995;26(7):1289–92.

CAS  Google Scholar 

Ibrahim GM, Chung C, Bernstein M. Competing for patients: an ethical framework for recruiting patients with brain tumors into clinical trials. J Neuro-Oncol. 2011;104(3):623–7.

CAS  Google Scholar 

Kimmel SE, Califf RM, Dean NE, Goodman SN, Ogburn EL. COVID-19 clinical trials: a teachable moment for improving our research infrastructure and relevance. Ann Intern Med. 2020;173(8):652–3.

Google Scholar 

Haidich AB, Ioannidis JPA. Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol. 2001;154(9):873–80.

CAS  Google Scholar 

Grill JD, Sperling RA, Raman R. What should the goals be for diverse recruitment in Alzheimer clinical trials? JAMA Neurol. 2022. https://doi.org/10.1001/jamaneurol.2022.2274 [cited 2022 Oct 17].

Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies. NIH Revitalization Act of 1993 Public Law 103-43 [Internet]. In: Mastroianni AC, Faden R, Federman D, editors. Women and health research: ethical and legal issues of including women in clinical studies: volume I: National Academies Press (US); 1994. Available from: https://www.ncbi.nlm.nih.gov/books/NBK236531/. Accessed 17 Oct 2022.

National Plan to Address Alzheimer’s Disease [Internet]. ASPE. Available from: https://aspe.hhs.gov/collaborations-committees-advisory-groups/napa/napa-documents/napa-national-plan. Accessed 17 Oct 2022.

Franzen S, Smith JE, den Berg E, Rivera Mindt M, Bruchem-Visser RL, Abner EL, et al. Diversity in Alzheimer’s disease drug trials: the importance of eligibility criteria. Alzheimers Dement. 2022;18(4):810–23.

CAS  Google Scholar 

The Administration for Community Living. 2020 profile of older Americans [Internet]. 2021 May. Available from: https://acl.gov/sites/default/files/Profile%20of%20OA/2020ProfileOlderAmericans_RevisedFinal.pdf. Accessed 10 Oct 2022.

2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021;17(3):327–406.

Raman R, Quiroz YT, Langford O, Choi J, Ritchie M, Baumgartner M, et al. Disparities by race and ethnicity among adults recruited for a preclinical Alzheimer disease trial. JAMA Netw Open. 2021;4(7):e2114364.

Google Scholar 

Raman R, Aisen P, Carillo MC, Detke M, Grill JD, Okonkwo OC, et al. Tackling a major deficiency of diversity in Alzheimer’s disease therapeutic trials: an CTAD Task Force report. J Prev Alzheimers Dis. 2022;9(3):388–92.

CAS  Google Scholar 

U.S. Food & Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials guidance for industry [Internet]; 2022. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations. Accessed 17 Oct 2022.

Mielke MM. Sex and gender differences in Alzheimer’s disease dementia. Psychiatr Times. 2018;35(11):14–7.

Google Scholar 

Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences between women and men in incidence rates of dementia and Alzheimer’s disease. J Alzheimers Dis. 2018;64(4):1077–83.

Google Scholar 

Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78(5):342–51.

CAS  Google Scholar 

Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, et al. Adeno-associated viral vector (serotype 2)–nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol. 2018;75(7):834.

Google Scholar 

Karlawish J, Cary MS, Rubright J, TenHave T. How redesigning AD clinical trials might increase study partners’ willingness to participate. Neurology. 2008;71(23):1883–8.

Google Scholar